Molloy, Persing and other Imugen crooks
Lisam01502
excludes OspA, an antigen specific for Lyme. Notice all the doctors hard at
work in developing new methods of how to NOT DETECT Lyme.
Of course the fact that Molloy, for example, worked for Imugen won't have had
any influence on the nature of his "advice" to Massachusetts Department of
Public Health's Lyme Disease Advisory Committee, now would it?
Of course not.
And that is just one, very small example.
Lisa
From the Imugen website:
IMUGEN PERSONNEL
Victor P. Berardi: CEO and SENIOR SCIENTIST, formerly Chief of Virology at the
Massachusetts State Laboratory Institute, Department of Public Health. Victor
has pioneered in the development of antibody capture EIA's, OspA-free testing
for Lyme disease and Lyme vaccine exposure, and the use of recombinant antigens
and PCR in the diagnosis of HGE. He is past Chairman, Clinical Virology,
Northeast Association for Clinical Microbiology and Infectious Diseases, and is
widely published in the area of laboratory diagnosis of all of the tick-borne
diseases.
Philip J. Molloy, M.D.: MEDICAL DIRECTOR, AND private rheumatology practice in
a highly endemic area for Lyme disease. Phil is a member of the Massachusetts
Department of Public Health's Lyme Disease Advisory Committee, and the
co-author of many publications on the serologic and immunologic
characterization of Lyme arthritis patients. He is currently actively involved
in the research on the correlation of clinical features and laboratory findings
in patients with various manifestations and stages of Lyme infection.
David H. Persing, M.D., Ph.D.: DIRECTOR OF LABORATORY SCIENCE, also serves as a
vice president and the Medical Director of the Infectious Disease Research
Institute of Corixa Corporation, Seattle, WA. David is formerly Associate
Director of Laboratory Medicine and Pathology, Mayo Medical School. He is the
author of numerous publications on diagnosing various infectious diseases, and
is on the editorial boards of the Journal of Clinical Microbiology, Molecular
Diagnosis, Diagnostic Microbiology and Infectious Diseases, Journal of
Infectious Diseases, Emerging Infectious Diseases, and New England Journal of
Medicine, and serves on the IDSA Practice Guidelines Committee on Lyme Disease.
Alan M. Sugar, M.D.: DIRECTOR OF ANTI-FUNGAL DIVISION, also serves as the
Director of the Clinical Mycology Center and Infectious Disease Consultant at
Boston University Medical Center. Alan is the editor-in-chief of the Journal of
Clinical Research Practice, and is on the editorial boards of Antimicrobial
Agents and Chemotherapy, Journal of Microbiology, Diagnostic Microbiology and
Infectious Diseases, and the International Journal of Antimicrobial Agents.
He is extensively published on all aspects of fungal infections and anti-fungal
agents.
Lionelle D. Wells, M.D.: DIRECTOR OF LABORATORY SERVICES, Fellow College of
American Pathologists, is licensed in Massachusetts and New York. Lee is
formerly the Director of Laboratory Services for Harvard Pilgrim Healthcare of
New England, and is the Massachusetts Eastern Divisional Commissioner for the
College of American Pathologists Accreditation Program, and is a faculty for
many CAP inspector training seminars nationally and internationally. He is
Assistant Clinical Professor of Pathology at Tufts University School of
Medicine, and Pathology Instructor, Harvard Medical School, Boston, MA.
Other Laboratory Personnel: IMUGEN employs a highly trained and experienced
staff.
Our SENIOR TECHNICIANS have devoted their past 15 years to specialized
serologic and molecular diagnostic test development for tick-borne infections,
and serve as Corporate Vice Presidents of IMUGEN. They have pioneered in the
development of capture EIA's, WB tests, OspA-free test reagents, recombinant
HGE test antigens, and PCR, and have published on test refinements for
tick-borne diseases in peer reviewed journals.
Kathleen
> From the Imugen website. Notice their pride in having developed a test that
> excludes OspA, an antigen specific for Lyme. Notice all the doctors hard at
> work in developing new methods of how to NOT DETECT Lyme.
> Of course the fact that Molloy, for example, worked for Imugen won't have had
> any influence on the nature of his "advice" to Massachusetts Department of
> Public Health's Lyme Disease Advisory Committee, now would it?
> Of course not.
> And that is just one, very small example.
> Lisa
Molloy is the "Medical Director". We think he owns
Imugen. He reported to the CDC at Dearborn that the
Steere method (CDC's current "Lyme disease" criteria)
was 14% accurate, and he was using the very strain Steere
used to invent this BOGUS Dressler/Steere Criteria
(which the CDC's Barbara Johnson recommended NOT using
at this very same conference. Confusing, I know, but
what can you expect from FRAUDs).
Imugen, when using Steere's strain (CDC criteria), was
only 14% accurate, but that is the standard from which the
CDC's standard evolved. I guess that was meant to guarantee
an 86% safe and effective vaccine???? Don't know. I do't think
like a crook....)
This was all reported to the FDA and the USDOJ.
We think Molloy owns Imugen with Steere.
Molloy later published with Persing and Sigal, that Sigal
and Steere actually could not read their Western Blots
in either Lyme vaccine trials. Weinstein was supposed to be in
charge of data safety monitoring for Sigal. DCF has that report
as well, which was why I reported DCF's attorney Sarah Gibson
to the USDOJ. I should think she would be responsible for
reporting FRAUD if she is a State's attorney???
So, Sigal executed a vaccine trial, and he found the Barbour
vaccine to be 92% safe and effective but actually he could not
even read his results. He must have thrown out even more data
than Steere did, but Sigal did not report his results in a
tabuilated way, so I could not look at the "data".
The MarDx test strips company was sold to TRINITY BIOTECH
in Dublin. That's where Jeremy Gray is, who is a member of
the EUCALB, the European version of the ALDF.
That's Molloy's story. I reported Imugen to the USDOJ
because their report forms say, "Less than 5 bands is NORMAL"
And they used to used NO CDC APPROVED STRAINS, and they
are formally "Partners" with Corixa and SmithKline.
Imugen even used a strain from Germany to test USA patients.
Imugen and L2 Diagnostics are the only two labs licensed
to use the OspA-less strain, which Persing (Corixa) patented,
but actually John Anderson discovered.
Imugen, Yale's L2 Diagnostics, CORIXA, SmithKline, and Aventis
are part of a formal network. Aventis is in France. The
Belgian SmithKline group represented SmithKline in Bethesda
at the FDA meeting. I guess I can see why---> Move that
fraudulent division over to Europe, where they can't be
touched by RICO law.
Imugen takes your blood, tells you you are normal
and we assume, sends that blood to Corixa. How else
is Corixa going to know what people here in the East
are exposed to? They're in Washington State.
Victor Berardi gave me a bunch of nonsense about
"molecular weight", back in June of 1999, when I called
and asked about their stupid FRG (Federal Republic of
Germany) strain, and why were they using that on USA
patients? Why would they not use local strains to
test local patients?.....
Berardi did not know I was a chemist, and I did not
tell him.
~Two weeks later, an announcement came through Pfizer about
Vijay Sikand looking for people to come to his office
in East Lyme, so he could pay them 100 dollars to sample
their EM rashes to look for new strains/infections.
Hmmm. What a coincidence.